摘要
胰高血糖素样肽1(GLP-1)是肠道L细胞分泌的肠促胰岛素激素,具有葡萄糖浓度依赖型降糖作用及β细胞保护作用,同时还具有减重、降压和降脂等心血管系统保护作用。艾塞那肽和利拉鲁肽均是天然GLP-1类似物,利拉鲁肽与人GLP-1同源性更高,且为长效制剂,它们克服了天然GLP-1易被降解的特点,保留了GLP-1的各种生理作用和治疗优势,发挥GLP-1的多效作用,降糖、β细胞保护、减重、降压、调脂全面干预多种心血管危险因素,且低血糖风险低,安全性好。GLP-1在治疗2型糖尿病及防治心血管风险方面具有独特优势。
Glucagon-like peptide-1（GLP-1） is an incretin hormone released by the L cell of gut in response to meal intake.It may address many of the needs of diabetes treatment such as glucose concentration-dependent hypoglycemia and β-cell protection,low risk of hypoglycemia,weight loss,reduction hypertension and unique cardiovascular protection.GLP-1 receptor agonist（incretin mimetic）,exenatide and liraglutide have long half-live because of their stability to enzymatic inactivation,especially liraglutide has longer half-live and high homology to the native hormone.Preclinical and clinical results showed that exenatide and liraglutide significantly improved glucose control and decreased risks of cardiovascular with low rates of hypoglycemia occurrence.GLP-1 receptor agonist has unique ad-vantages for type 2 diabetes mellitus treatment and cardiovascular disease risk prevention.
出处
《医学综述》
2011年第8期1195-1197,共3页
Medical Recapitulate
关键词
胰高血糖素样肽
艾塞那肽
利拉鲁肽
2型糖尿病
心血管疾病
Glucagon-like peptide
Exenatide
Liraglutide
Type 2 diabetes mellitus
Cardiovascular disease
